Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Peregrine Pharmaceuticals Receives FDA Clearance to Initiate Tarvacin & #153 Anti-Viral Clinical Trial

By Pharmaceutical Processing | June 2, 2005

Peregrine Pharmaceuticals, Inc. has announced that it has received clearance from the FDA for its Tarvacin&#153 anti-viral Investigational New Drug application (IND). The initial clinical protocol under this IND is a phase 1 dose escalation study designed to evaluate a single intravenous infusion of Tarvacin&#153 in up to 32 patients with chronic Hepatitis C virus (HCV) infection.

“We are excited to begin exploring another clinical indication for Tarvacin&#153,” said Joseph Shan, senior director of clinical and regulatory affairs. “We anticipate this study will accrue patients rapidly due to the prevalence of chronic Hepatitis C infections in the U.S. and the need for new therapies to treat this disease.”The objectives of the phase 1 clinical protocol are to evaluate safety, pharmacokinetics and viral load in patients chronically infected with HCV who have failed to respond or who have relapsed after the current standard treatment with pegylated interferon plus ribavirin. Up to 50% of patients receiving the combination of pegylated interferon plus ribavirin either relapse or do not respond after treatment.

“Receiving clearance to begin this initial Tarvacin&#153 anti-viral clinical trial is an important milestone for the program,” stated Steven King, president and CEO. “We are continuing to evaluate Tarvacin’s&#153 potential for the treatment of other enveloped virus infections, including HIV, influenza A, influenza B, avian flu, as well as viruses included on the government’s bioterrorism watchlist such as Lassa fever and Marburg virus.”

According to the World Health Organization, there are an estimated 2.7 million people in the U.S. and 170 million people worldwide with chronic HCV infection, which is the most common chronic bloodborne infection in the United States and the leading indication for liver transplantation. There is no known vaccine against HCV.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE